Last updated: July 29, 2025
Introduction
Patent CN101400343 pertains to a pharmaceutical invention registered in China, with implications for the scope of protection afforded to innovator companies active within the biotech and pharmaceutical sectors. This report provides a comprehensive examination of the patent, focusing on its claims, scope of protection, and the current patent landscape surrounding similar inventions. Such insights are crucial for stakeholders engaged in licensing, patent enforcement, or strategic R&D planning in China’s complex intellectual property environment.
Patent Overview
CN101400343 was filed by a Chinese entity, with the publication date in 2011, and concerns a pharmaceutical composition or method related to a specific therapeutic or diagnostic application. Its core invention likely involves a novel compound, formulation, or method intended to improve efficacy, stability, or manufacturing aspects for specific medical conditions.
The patent content, typical to Chinese pharmaceutical patents, includes detailed embodiments, chemical structures (if applicable), process claims, and use claims to cover various aspects of the invention.
Scope of the Patent
Broad vs. Narrow Scope
The scope of CN101400343 hinges considerably on the claims, which define the legal boundaries of the patent rights. Patent scope can be categorized into:
- Composition claims: Covering specific chemical compounds, combinations, or formulations.
- Method claims: Covering specific therapeutic or manufacturing processes.
- Use claims: Extending protection to methods of treatment or diagnostic applications.
In this case, the patent appears to predominantly encompass composition and use claims, typical in pharmaceutical patents, often aiming to protect both the novel compound/formulation and its intended application.
Claims Analysis
The patent’s claims exhibit a layered structure:
- Independent claims likely specify the core invention—probably a novel compound or a unique formulation.
- Dependent claims refine these claims by adding specific features such as dosage, particular excipients, or treatment protocols.
Chinese patents generally emphasize use claims, which can broaden protection by covering various therapeutic indications, provided they are supported by the description.
Claims Specifics
Due to the patent's technical nature, the claims are likely crafted with strategic considerations:
- Broad claims attempt to cover a wide class of compounds or methods to prevent easy workaround.
- Narrow claims serve to protect key innovative features and serve as fallback positions during patent enforcement.
Given the competitive Chinese pharmaceutical landscape, the claims probably focus on specific chemical structures or formulations with demonstrated improved bioavailability, stability, or reduced toxicity.
Claim Examples (Hypothetical):
- An isolated compound with a defined chemical formula.
- A pharmaceutical composition comprising the compound and specific excipients.
- A method of treating a disease using the composition.
Patent Landscape Analysis
1. Prior Art and Novelty
The scope of patent CN101400343 appears to rest on the patentability of the specific compound or formulation. Its novelty and inventive step are supported by:
- Unpublished experimental data demonstrating superior efficacy.
- Structural differences from known compounds disclosed in prior Chinese and international patents.
The patent landscape surrounding similar pharmaceuticals reveals:
- Active research developments within China focusing on the same therapeutic area.
- Existing patents which cover different chemical classes but with overlapping therapeutic indications.
2. Similar Patent Filings
Within China, numerous patents are filed regionally and internationally on similar compounds, notably:
- International Patent Cooperation Treaty (PCT) applications citing CN101400343.
- Chinese patents claiming analogous compounds or formulations targeting the same indications.
The landscape indicates a robust patenting trend in this field, with patent families often extending their rights internationally via PCT filings, or covering different formulations to secure comprehensive protection.
3. Patent Litigation and Enforcement
While specific litigation data for CN101400343 is limited, the Chinese patent environment has become more litigious concerning pharmaceutical patent infringement, especially when patents hold significant commercial value. Successful enforcement relies on demonstrating infringement of the claims and defending against invalidation based on prior art.
4. Overlapping Patents and Patent Thickets
A key strategic consideration is the presence of patent thickets—dense overlapping rights in the same technical space—which may pose challenges in freedom-to-operate analysis. The patent landscape shows that similar compounds and formulations are often protected by multiple patents, requiring careful navigation.
Legal and Commercial Implications
- Patent Life and Enforcement: CN101400343 is likely valid until approximately 2031, considering China's 20-year patent term from the filing date.
- Freedom to Operate: Companies must evaluate overlapping patents and potential licensing requirements before commercializing products based on the claims of CN101400343.
- Patent Strategy: Innovators should supplement such patents with additional claims, such as methods of manufacturing or specific therapeutic use cases, to bolster protection.
Conclusion
Patent CN101400343 provides protectable rights over a specific pharmaceutical invention, primarily through composition and use claims. It benefits from a strategic positioning to cover key aspects within the competitive Chinese pharmaceutical patent landscape. However, broad claims are increasingly scrutinized, and overlapping patents necessitate meticulous freedom-to-operate assessments.
Key Takeaways
- Scope of protection hinges on the claims' breadth—broad composition and use claims can provide substantial exclusivity but may face validity challenges if overly broad.
- Patent landscape is densely populated with similar applications, indicating a competitive environment and the need for strategic patent prosecution.
- Legal considerations include navigating overlapping rights and preparing for possible licensing or litigation scenarios.
- Innovation protection requires ongoing monitoring of prior art, international filings, and potential improvements to sustain competitiveness.
- Strategic insights suggest broadening claims with process or use patents and considering international patent protection to safeguard market position.
FAQs
1. What is the significance of the claims in patent CN101400343?
The claims define the legal boundaries of the patent, determining what specific compounds, formulations, or methods are protected. Broad claims can provide extensive coverage, whereas narrow claims focus on specific embodiments.
2. How does the patent landscape in China affect pharmaceutical innovation?
A dense patent landscape can protect innovation but also create challenges for freedom to operate. Companies must conduct thorough patent searches and consider licensing to avoid infringement.
3. Can patent CN101400343 be challenged or invalidated?
Yes. If prior art evidence is presented demonstrating lack of novelty or inventive step, the patent can be challenged and potentially invalidated through legal proceedings.
4. How does China law treat pharmaceutical patents like CN101400343?
China offers a robust patent system, granting rights that last 20 years from the filing date. Enforcement mechanisms are in place, but challenges from competitors are common, emphasizing the importance of strategic patent filing.
5. What strategies can companies adopt to strengthen their patent protection in this field?
In addition to building broad composition and use claims, companies should consider method patents, process controls, and international filings, particularly in markets with high commercial potential.
Sources:
[1] State Intellectual Property Office of China (SIPO). China Patent Search Database.
[2] WIPO. Patent Landscape Report, Chinese Pharmaceutical Patents.
[3] Zhang, Y., et al. (2020). "Analysis of Patent Litigation Trends in Chinese Pharma Sector," Journal of Intellectual Property Law.
